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Background: Human epidermal growth factor receptor-2 (Her-2) is over expressed in approximately 25-30% of all
primary breast tumors resulting in a distinctive breast cancer subtype associated with a poor prognosis and a
decrease in overall survival. Trastuzumab (Herceptin®), an anti-Her-2 monoclonal antibody, has dramatically altered
the prognosis of Her-2 positive breast cancer. Trastuzumab is, however, associated with primary and acquired
resistance.
Aim and methods: To investigate the in-vitro effects of trastuzumab on cell viability (tetrazolium conversion assay),
cell cycling (propidium iodide staining), apoptosis (executioner caspases and annexin-V) and relative surface Her-2
receptor expression (anti-Her-2 affibody molecule) in Her-2-positive (SK-Br-3) and oestrogen receptor positive
(MCF-7) breast adenocarcinoma cells and to determine potential augmentation of these effects by two
endogenous ligands, epidermal growth factor (EGF) and heregulin-β1 (HRG- β1).
Results: Cell viability was decreased in SK-Br-3 cells by exposure to trastuzumab. This was associated with G1
accumulation and decreased relative surface Her-2 receptor density, supporting the cytostatic nature of
trastuzumab in vitro. SK-Br-3 cells exposed to EGF and heregulin-β1 produced differential cell responses alone and
in combination with trastuzumab, in some instances augmenting cell viability and cell cycling. Relative surface
Her-2 receptor density was reduced substantially by trastuzumab, EGF and heregulin-β1. These reductions were
amplified when ligands were used in combination with trastuzumab.
Conclusion: Cell type specific interactions of endogenous ligands appear to be dependent on absolute
Her-receptor expression and cross activation of signaling pathways. This supports the notion that receptor density
of Her-family members and multiplicity of growth ligands are of mutual importance in breast cancer cell
proliferation and therefore also in resistance associated with trastuzumab.
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The evolutionary ancient human epidermal growth fac-
tor receptor (Her) family is composed of the structurally
related tyrosine kinases Her-1 (EGFR), Her-2, Her-3 and
Her-4, which play a fundamental role in regulating cell
functions including proliferation, adhesion, motility and
survival [1-3]. Her-family receptors govern different func-
tions and have different properties. Furthermore, Her-1,
Her-3 and Her-4 possess the affinity for binding multiple* Correspondence: tracey.hurrell@up.ac.za
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distribution, and reproduction in any mediumligands [4,5]. Ligands for Her-1 include EGF, transforming
growth factor-α, amphiregulin, betacellulin, epigen, epiregulin
and heparin binding EGF-like growth factor while ligands
for Her-3 and Her-4 include the isoforms of four structur-
ally related heregulins [5].
In contrast with the others, Her-2 receptors have no
known ligands and are thus designated as orphan receptors
[6-8]. Rather, activation of these receptors is achieved by
the formation of interactive dimers, either spontaneously
with Her-2 receptors or with other ligand-activated family
members. Her-3 receptors are incapable of intrinsic kinase
activity [9]; thus ordinarily, neither Her-2 nor Her-3 areCentral Ltd. This is an open access article distributed under the terms of the
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Hurrell and Outhoff Cancer Cell International 2013, 13:97 Page 2 of 9
http://www.cancerci.com/content/13/1/97capable of linear signaling in isolation, which implies
that they have strongly interdependent signaling char-
acteristics [5].
Modularity, redundancy and the capacity for combination
interactions are important in signal diversification of
the Her-signaling network [6]. These horizontal networks
can be detrimental when over expressed receptors spon-
taneously homo-dimerize or bias the dimer types formed
[10]. Equally, over-production of endogenous ligands
such as EGF and heregulin-β1 may over-activate these
networks as part of the carcinogenesis process [11,12].
Approximately 25-30% of all primary breast tumors over
express Her-2 receptors, [11] which makes the Her-2
receptor a clinically relevant molecular constituent of
breast cancer associated with a poor prognosis and a
decrease in overall survival [13].
Trastuzumab (Herceptin®; Genentech Inc, South San
Francisco, CA), is a recombinant, DNA derived, human-
ized, anti-Her-2 monoclonal antibody which selectively
targets subdomain IV of the extracellular domain over
expressed Her-2 receptors and is licensed as a therapy
for Her-2 positive breast cancer.
Trastuzumab, while governed by strict eligibility criteria,
has become an integral component of treatment regi-
mens and has dramatically altered the natural progression
of this breast cancer subtype [14,15]. Initially, studies
reported that in trastuzumab-treated patients, Her-2
status remained stable over time. However, discordances
between primary and metastatic sites are now reported
to reach up to 30%. This dynamic receptor expression
confounds stratification of patients into appropriate
therapeutic categories [16].
Furthermore, despite having enhanced selectivity for
Her-2 over expressing cancerous cells, [17] trastuzumab
efficacy is hampered by significant variations in response
and the development of resistance [18,19]. Retrospective
analyses with the paradigm of targeted therapies in other
cancer subtypes (such as non-small-cell lung cancer)
suggest that only 30-40% of patients derive substantial
clinical benefit from molecular targeted therapies and
that long term disease remission is not achieved in up
to 80% of cancer patients [20,21].
Recent data from the Hermine observational study,
designed to evaluate outcomes in patients with meta-
static breast cancer receiving trastuzumab in routine
clinical practice, illustrated that while survival benefit
was evident for patients on first line trastuzumab treatment,
177 (80.09%) patients from the cohort experienced disease
progression within the follow up period [22].
The aim of this study, therefore, was to investigate the
ability of the endogenous Her-receptor activating ligands
EGF (Her-1 ligand) [5] and heregulin- β1 (Her-3 and Her-4
ligand) [23,24] to influence the efficacy of trastuzumab
in Her-2 positive breast adenocarcinoma in order togain a clearer understanding of what may occur when
the biological context is altered.
Results and discussion
Tight integration and redundancy of the Her-receptor
system creates contemporary challenges for targeted
therapies such as trastuzumab, including acquired and
de novo resistance [25] associated with, among others,
truncated Her-2 (p95-Her-2) forms, repackaging of in-
tegral cell survival proteins and up regulation of alter-
native signalling pathways [19,26]. Here we discuss the
ability of two endogenous molecules to alter in vitro
characteristics of trastuzumab and assess the implications
for targeted therapy.
The greater the dependence of cells on Her-2 receptor
mediated growth and transformation, the greater the
anti-proliferative effect of trastuzumab [27]. Not sur-
prisingly, trastuzumab was unable to affect cell viability
in MCF-7 cells. Trastuzumab (1–500 μg/ml) induced sub-
stantial anti-proliferative effects in SK-Br-3 cells however
(Figure 1), which suggests an extensive reliance of these
cells on Her-2 receptors for propagation of cell growth
[28]. However, there was no difference in cell viability at
different concentrations of trastuzumab. It was speculated
that at higher concentrations, the binding domains were
saturated or that Her-2 receptors were internalised and
degraded or unable to recycle back to the surface for
further trastuzumab binding. Saturating concentrations of
trastuzumab (50 – 100 μg/ml) were used for further studies
to ensure continuous effects on the seeded cell population
as well as on cell progeny.
Trastuzumab influenced cell cycle kinetics by inducing
significant G1 accumulation in MCF-7 at 72 hours only
(Figures 2 and 3) and in SK-Br-3 cells at 24, 48 (data
not shown) and 72 hours (Figure 2). This is consistent
with other data where trastuzumab has been found to
interfere with Her-2 receptor signaling and consequently
inhibit G1-S phase transition [29,30].
While targeted therapies have achieved great com-
mendation for their selectivity and specificity, efficacy
remains dependent on the continual and persistent pres-
ence of targets. Unlike MCF-7 cells, which were impervious
to the effects of trastuzumab, SK-Br-3 cells demonstrated
a significant decrease in Her-2 receptors when exposed to
trastuzumab from as early as 6 hours [68.69% ± (1.14)].
Near identical decreases were obtained at 12, 24 (Figure 4)
and 48 hours suggesting that cells were not re-accumulating
on the surface within the period of time assessed. Taken
together, the dose-independent decrease in cell viability and
consistent G1 accumulation in SK-Br-3 cells may have been
due to the reduction in Her-2 receptors, a threshold above
which is required for further trastuzumab efficacy.
Binding of Her-receptor ligands results in the formation
of dimer complexes. Subsequent auto-phosphorylation
Figure 1 Cell viability in MCF-7 and SK-Br-3 cells. Mean (± SEM) cell viability determined using a tetrazolium conversion assay. Cells were first
exposed to trastuzumab ranging from 1 μg/ml to 500 μg/ml. The result was a reduction in cell viability in SK-Br-3 cells which was not seen in
MCF-7 cells. Cells were then exposed to a saturating concentration of trastuzumab combined with either EGF (400 ηg/ml) or HRG-β1 (200 ηg/ml).
These endogenous biological molecules significantly abrogated cell viability observed for trastuzumab (Table 1).
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cell proliferation [31]. The pleiotropic biological activ-
ity of Her-ligands creates doubt as to the ability of
targeted therapies to elicit clinically valuable responses in
the presence of these ligands. Exposing MCF-7 cells to EGF
(400 ηg/ml) or heregulin-β1 (200 ηg/ml) resulted in in-
consequential responses. However, both ligands appeared
to sensitize MCF-7 cells to the anti-proliferative effects of
trastuzumab: when cells were exposed to the combination
of growth factors and trastuzumab, a significant decrease
in viability was noted, compared to each agent used alone.
(Table 1). These reductions, when viewed in isolation may
suggest that trastuzumab may influence Her-2 negative,
estrogen receptor positive breast cancer, particularly in the
presence of overexpressed Her-family ligands.
This correlates with others who have demonstrated
trastuzumab’s ability to inhibit heregulin-induced pro-
liferation of these cells, in spite of normal expression
of Her-2 receptors [32,33]. However, in these experiments,
trastuzumab merely diminished the enhanced cell viability
induced by Her-family ligands, which seldom have altered
expression levels in Her-2 negative breast cancer subtypes.
It does however highlight the ability to manipulate signaling
pathways of subtypes of breast cancer based on the
presence of endogenous ligands and suggests that our
scope of clinical assessments is too narrow to confer
positive clinical outcomes in circumstances confounded
by endogenous ligands. Further elucidation of molecularcrosstalk between oestrogen and Her-family growth sig-
nalling pathways which become activated under various
physiological conditions by endogenous ligands is integral
in determining therapeutic strategies.
That no apoptosis (via detection of executioner caspases
or annexin-V) was detected for any agent used alone or in
combination with trastuzumab despite significant apoptosis
being observed for the positive control (data not shown),
suggested that mechanisms for altered in vitro cell viability
were cytostatic, possibly due to alterations in cell cycle
kinetics, rather than being cytotoxic. EGF, a prolifera-
tive Her-1 ligand, should theoretically accelerate cell
cycle kinetics and increase the number of cells entering
the G1 phase. However, in this study, EGF exposure
resulted in negligible effects on the cell cycle of MCF-7
cells, which correlated with the lack of additional cell
growth. Notably, G1 phase accumulation was observed
in the cells exposed to the EGF-trastuzumab combin-
ation [38.54% (± 1.25)] and while increased compared
to the control, G1 accumulation remained statistically
significantly lower than trastuzumab.
Heregulin binding assays have quantified Her-3 and
Her-4 receptors and indicate that SK-Br-3 cells express
more than double the number of Her-3 and Her-4 recep-
tors per cell than MCF-7 cells and are thus arbitrarily
characterized as having intermediate and high levels of re-
ceptors respectively [34]. In MCF-7 cells, heregulin dem-
onstrated no cumulative effects on cell cycle distribution
A B
Figure 3 Column graphs of cell cycle analysis. Following exposure for 72 hours to trastuzumab, heregulin-β1 or the heregulin-β1-trastuzumab
combination histograms were analyzed with deconvolution software and expressed as column graphs. A) Significant alterations within the G1
phase were observed in MCF-7 cells exposed to trastuzumab and the heregulin-β1-trastuzumab combination; B) Significant alterations in the
S-phase were observed in SK-Br-3 cells exposed to heregulin-β1 compared to the untreated control. [EGF did not perpetuate noteworthy
















Figure 2 Flow cytometry histograms analysed with deconvolution software. Gaussian curves were utilised to divide histograms into G1
phase (left), S phase (centre) and G2 phase (right) A) Untreated MCF-7 cells in DMEM with 10% FCS; B) Trastuzumab treated MCF-7 cells after
72 hours illustrating G1 accumulation; C) Untreated SK-Br-3 cells in RPMI with 10% FCS; D) Trastuzumab treated SK-Br-3 cells after 24 hours
illustrating G1 accumulation.

























Figure 4 Overlay plots and column graphs comparing the relative Her-2 receptor density in SK-Br-3 cells. A) Overlay plots of the
unstained (black), stained (green) and the positive control, geldanamycin (red) with the associated geometric mean; B) Overlay plots of the
unstained (black), stained (green) and cells exposed to trastuzumab (blue) with the associated geometric mean; C) Overlay plots of the unstained
(black), stained (green) and cells exposed to heregulin-β1 (pink) or the heregulin-β1-trastuzumab combination (purple) with the associated geometric
mean; D) Fluorescence (x-mean) intensity of triplicate runs, expressed as a percentage of untreated control (standardised to 100%). Concurrent heregulin-
β1 abrogated relative Her-2 receptor density observed for trastuzumab. Trastuzumab, heregulin-β1 and the heregulin-β1-trastuzumab combination
illustrated a progressive decrease in Her-2 receptor density at 24 hours. Similar significance trends were observed in SK-Br-3 cells exposed to EGF [56.82%
(± 2.82)] and the EGF-trastuzumab combination [45.01% (± 1.06)].
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Table 1 Cell viability in MCF-7 and SK-Br-3 cells
MCF-7 SK-Br-3
Trastuzumab (50 μg/ml) 95.35% (± 2.27) 72.58% (± 1.31)
(EGF + T50: P < 0.001)
EGF (400 ηg/ml) 101.70% (± 1.84) 81.43% (± 2.46)
(EGF + T50: P < 0.001)
EGF (400 ηg/ml) + Trastuzumab (50 μg/ml) 89.52% (± 1.95) 89.40% (± 2.20)
(Trastuzumab50: P < 0.05)
HRG (200 ηg/ml) 107.01% (± 2.42) 115.40% (± 2.08)
(Trastuzumab50: P < 0.001) (Trastuzumab50: P < 0.001)
HRG (200 ηg/ml) + Trastuzumab (50 μg/ml) 93.76% (±2.52) 114.50% (± 1.98)
(HRG: P < 0.001) (Trastuzumab50: P < 0.001)
Mean (± SEM) cell viability determined using a tetrazolium conversion assay.
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was noted, suggesting accelerated cell cycle kinetics to
accompany the increased cell viability.
Her-2 monoclonal antibodies are capable of inhibiting
heregulin-induced activation of PI3-kinase and downstream
targets (Akt) in MCF-7 cells [23]. This inhibition could
be the mechanism by which trastuzumab abrogated
heregulin-induced mitogenic proliferation in our cells.
The accompanying G1 accumulation in cells exposed
to a combination of heregulin and trastuzumab, which
mimicked that of trastuzumab, may also be attributed
to inhibition of this pathway. Although we were unable to
observe alterations in Her-2 receptor density, perhaps due
to the low constitutive Her-2 receptor number of MCF-7
cells, the presence of these endogenous ligands appeared to
influence the mechanisms that we and others have assessed
for trastuzumab in MCF-7 cells.
Although mRNA can be a deceptive framework for
referencing ligand efficacy, quantitative analysis shows
that SK-Br-3 cells express approximately ten-times more
Her-1 protein than MCF-7 cells [35] which implies a
greater potential for response to EGF. However, EGF
resulted in a surprising decrease in cell viability of SK-Br-3
cells. This was counteracted by concurrent trastuzumab
exposure in favor of increased cell viability (Table 1).
Synergistic effects of over expressing receptors within cel-
lular transformation have been suggested [24]. However,
sustained activation of Her-1 and Her-2 receptors may
activate pathways, paradoxically leading to cell death even
in the presence of proliferative ligands [36,37].
EGF exposure resulted in a substantial decrease in
Her-2 receptor density, implying that Her-2 signaling
was reduced. When combined with trastuzumab, the
decline in Her-2 receptor density was even greater.
Tikhomirov et al. noted that rapid internalization of Her-1
and subsequent lysosomal degradation occurs after ligand
binding [37]; Her-2 receptors may be internalized as part of
this interactive dimer complex. Here the authors suggestthat reduction of Her-2 receptors by trastuzumab may alter
the balance of Her-1:Her-2 co-expression, and in doing so,
EGF potentiates less of an anti-proliferative effect. Thus in
selective circumstances, where multiple Her-receptors are
over-expressed, trastuzumab may alter the co-expression
ratio in favor of synergistic proliferative effects.
Heregulin-β1-induced propagation of cell growth of SK-
Br-3 cells (Table 1) was consistent with the fact that these
cells also express Her-3 receptors, and was accompanied
by an increased number of cells in the S-phase of the cell
cycle at 72 hours (Figure 3). Her-2:Her-3 heterodimers are
considered the most potent signal transduction complex
with the highest mitogenic potential [5,17]. Increased
cell growth by heregulin-β1 could also be attributed to po-
tentiation of already increased basal Akt activity asso-
ciated with Her-2 receptor over-expression [23]. Thus,
as a potent stimulator, heregulin-β1 may be capable of
compensating for the inhibition ordinarily elicited by
trastuzumab [38]. This was corroborated when concurrent
exposure with trastuzumab did not affect the cell growth
potential of heregulin-β1. Once again, the potency of
the Her-2:Her-3 dimer pair could help explain why
trastuzumab had a negligible effect on these cells when
combined with heregulin-β1.
Although heregulin-β1 propagated cell growth, sub-
stantial reductions in Her-2 receptors were observed
when SK-Br-3 cells were exposed to the ligand. An even
greater reduction of Her-2 receptors was observed when
heregulin-β1 was used in combination with trastuzumab
(Figure 4). This could have serious implications for
trastuzumab efficacy, as the target is diminished. Daly et al.
previously also observed a decrease in Her-2 receptors in
response to heregulin-β1 after 48 hours in these cells [39].
Reduction in surface Her-2 receptors by EGF and
heregulin-β1 implicates both growth ligands in limiting
trastuzumab efficacy and ultimately resulting in disease
progression. If this remains true for additional Her-family
ligands, assessing expression levels of ligands will have
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of trastuzumab eligibility.
In our experiments, Her-2 receptors were assessed
using whole cells because trastuzumab efficacy is solely
dependent on the accessibility of receptors on the cell
surface. Receptor analysis using lysed cells potentially
also detects ubiquitin-targeted receptors which are not yet
degraded, or internalised receptors capable of recycling; this
may skew data in favour of a higher receptor density. EGF
and heregulin-β1 appeared to promote Her-2 receptor in-
ternalization in the form of heterodimers which augmented
the reduction of Her-2 receptor in trastuzumab exposed
cells. However, the fate of receptors upon internalization
was not elucidated as it was beyond the scope of this ex-
periment. While the overall number of receptors within
a cell may not change in response to trastuzumab, the
ability of receptors to be restored to the cell surface upon
removal of trastuzumab or ligands remains inconclusive.
Further complicating this research is the ability of factors
such as fetal calf serum (FCS) and seeding density to
provide differential responses in endpoint experiments
dependent on the heregulin isoforms used [39]. While
heregulin-β1 was used in these experiments the results are
intriguing and open avenues for the study of alternative
isoforms. Understanding and monitoring the molecular
subtypes of cancer and divergence of signaling pathways
in response to targeted therapy is now required to ensure
the therapeutic benefit of trastuzumab.
While the use of cytotoxic-conjugated-antibodies is being
researched extensively, antibody-dependent cell-mediated
cytotoxicity (ADCC) was not assessed in this study. This
is due to the fact that efficacy of trastuzumab in a clinical
context is highly dependent on the maintenance of a con-
tinuous and consistent receptor threshold. If this is not
done, as was seen over the time points assessed here then
ADCC would be negligible due to the absence of sufficient
target receptors.
Conclusion
Cell type specific interactions of endogenous ligands appear
to be dependent on the absolute Her-receptor expression
and cross activation of signaling pathways. While a
threshold of surface Her-2 receptors is required to en-
sure trastuzumab binding, efficacy may be dependent
on co-receptor expression ratios, as opposed to only
Her-2 receptors, as a prognostic indicator and marker
for targeted therapy. In this study, Her-2 receptor status
was greatly influenced by endogenous growth factors. The
reduction in surface Her-2 receptors diminished the avail-
ability of targets for trastuzumab and thereby differentially
altered the efficacy parameters assessed for trastuzumab.
It remains unclear whether these alterations in receptor
abundance are maintained for sufficient periods to be clin-
ically relevant. However, this data supports the notion thatreceptor density of Her-family members and multiplicity
of growth ligands are of mutual importance in prolifera-
tion. This may provide insight into the role of endogenous
Her-ligands in the emergence of resistance and have far-
reaching consequences for targeted therapy and long-term
disease remission.
Methods
This study was approved by the Faculty of Health Science
Student Research Ethics Committee of the University
of Pretoria.
Human breast adenocarcinoma cells
Adherent breast adenocarcinoma cell lines included estrogen
receptor positive MCF-7 cells (ATCC Number HTB-20TM)
which express physiologically normal levels of Her-2 recep-
tors, and SK-Br-3 cells (ATCC Number HTB-30TM) which
over-express Her-2 receptors, obtained from American Type
Culture Collection (ATCC; Manassas, USA). MCF-7 cells
were deemed an ideal control as these cells express estrogen
receptors, enabling the potential for receptor crosstalk, while
both MCF-7 and SK-Br-3 cells express all members of the
Her-family of receptor tyrosine kinases to varying degrees.
MCF-7 and SK-Br-3 cells were maintained in DMEM and
RMPI 1640 medium (Sigma-Aldrich; St Louis, USA) re-
spectively, supplemented with 10% heat-inactivated fetal calf
serum (FCS) (PAA Laboratories; Pasching, Austria) and 1%
penicillin-streptomycin (BioWhittaker; Walkersville, USA).
Cells were seeded at 1×104 cells per well or at 1.5×105
cells per 25 cm2 flask and maintained in a humidified
atmosphere containing 5% CO2 at 37°C.
Trastuzumab and growth factors
Trastuzumab (Herceptin®) was kindly donated by Roche
Pharmaceuticals (Johannesburg, South Africa). Recombin-
ant human epidermal growth factor and heregulin-β1
were obtained as lyophilized powder from Sigma-Aldrich
(St Louis, USA). Growth factors were reconstituted in
filter sterilized (0.22 μM) dH2O while trastuzumab was
reconstituted in bacteriostatic water as per manufacturer’s
instructions. Cells were exposed to saturating concentra-
tions of EGF (400 ηg/ml) or heregulin-β1 (200 ηg/ml) to
determine baseline effects. Additionally, cells were exposed
to trastuzumab (1–500 μg/ml), to determine a dose re-
sponse and a saturating concentration of trastuzumab
then combined with either EGF or heregulin-β1.
Tetrazolium conversion assay
Cell viability was determined using a quantitative-
colorimetric conversion assay of 3-[4, 5-dimethylthiazol-
2-yl]-2, 5-diphenyl tetrazolium bromide (MTT) after
exposure for 96 hours. Cells were incubated with 20 μl
MTT solution (5 mg/ml) (Sigma-Aldrich; St Louis, USA)
for 3 hours, washed with phosphate buffered saline
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product solubilized in dimethyl sulphoxide (Merck
Chemicals; Darmstadt, Germany). Plates were read
spectophotometrically using an ELx800uv universal
microplate reader (Bio-TEK Instruments, INC) with a dual
wavelength of 570 nm and 630 nm. Cell-free medium and
drug controls were included to discern reactivity of MTT
with extraneous variables other than cells.
Cell cycle analysis
The cell cycle was analyzed using interchelating, fluorescent
propidium iodide with flow cytometric detection at 24,
48 and 72 hours. Decanted medium and trypsinized
cells were washed (1% FCS in PBS), fixed in 70% ethanol
(Merck Chemicals; Darmstadt, Germany) and stored over-
night at 4°C. Cell pellet was re-suspended in 1 ml of
propidium iodide (40 μg/ml) (Sigma-Aldrich; St Louis, USA)
staining solution containing Triton-X (Sigma-Aldrich; St
Louis, USA), a non-ionic surfactant (0.1% v/v), and DNase
free RNase (100 μg/ml) (Sigma-Aldrich; St Louis, USA).
Samples were incubated at 37°C for 40 minutes and ana-
lyzed using a Cytomics FC500 (Beckman Coulter).
Executioner caspase assay
Cells were exposed to trastuzumab, growth factors or the
positive control [staurosporine, 10.7 μM (Sigma-Aldrich;
St Louis, USA)] between 4 and 30 hours. Cell lysis buffer
[10 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic
acid (HEPES), 1 mM phenylmethylsulfonyl fluoride
(PMSF), 5 mM 3-[(3-cholamidopropyl)dimethylammonio]-
1-propanesulfonate (CHAPS) (Merck Chemicals; Darmstadt,
Germany), 2 mM ethlene-diamine-tetra-acetic acid (EDTA),
and 5 mM β-mercaptoethanol (Labchem; Johannesburg,
RSA)] was added and plates incubated for 40 minutes on ice
followed by addition of 125 μl assay buffer [20 mM HEPES,
2 mM EDTA and 5 mM β-mercaptoethanol] containing
5 μM of Ac-DEVD-AMC substrate (Sigma-Aldrich; St
Louis, USA). Plates were incubated overnight at 37°C to
allow Ac-DEVD-AMC substrate hydrolysis by activated
executioner caspases-3 and −7, and the released fluor-
escent product was read using a FLUOstar OPTIMA
(BMG LABTECH) with excitation-emission wavelengths of
350 nm and 450 nm respectively.
Apoptosis-necrosis
Later apoptotic hallmarks were assessed after exposure
for 48 or 72 hours using FITC conjugated annexin-V,
counterstained with propidium iodide to assess membrane
integrity. Cells were washed and re-suspended in 100 μl of
annexin-V binding buffer [10 mM HEPES, 150 mM NaCl,
5 mM KCL, 1.8 mM CaCl2 and 1 mM MgCl2 (Merck
Chemicals; Darmstadt, Germany)] followed by staining with
2.5 μl of annexin-V-FITC (Sigma-Aldrich; St Louis, USA).
Samples were incubated in the dark for 10 minutes and3 μl of propidium iodide (3 mM) (Sigma-Aldrich; St
Louis, USA) was added shortly prior to acquisition using a
Cytomics FC500 (Beckman Coulter).
Relative Her-2 receptor density
Relative Her-2 receptor density was determined after cells
were exposed to trastuzumab, growth factors or the posi-
tive control [geldanamycin, 0.35 μM (Tocris Bioscience;
Ellisville, USA)] for 12, 24 and 48 hours, using an anti-
Her-2-FITC affibody molecule (Abcam; Cambridge, UK)
which is a protein composed of a three-helix bundled at
the unique C-terminal cysteine which does not compete
for Her-2 binding with trastuzumab [40]. Samples were
washed twice (1% FCS in PBS) and the single cell suspen-
sion labeled with the affibody molecule (final concentra-
tion: 3.7 μg/ml) and incubated on ice for 30 minutes. Cells
were washed prior to acquisition using a Cytomics FC500
(Beckman Coulter). The mean-fluorescence intensity was
expressed relative to the untreated control.
Statistics
A minimum of three independent inter-day repeats were
conducted with a minimum of three intra-day repeats
where required. Cell cycle histograms were analysed
using deconvolution software, uncovering the underlying
distribution by fitting Gaussian curves using WinCycle
MultiCycle V3.0 for Windows (WinCycle Software;
Washington, USA). Histrograms for relative Her-2 re-
ceptor density were analysed using CyflogicTM software
(CyFlo, Ltd, Finland) and the x-mean and geometric mean
determined. Non-parametric, Kruskal-Wallis, test was
conducted to compare the mean values obtained for
trastuzumab versus EGF or heregulin-β1 alone versus the
trastuzumab-growth factor combinations. Dunn’s mul-
tiple comparison test was used for post-hoc analysis with
significance set at p-value < 0.05. Statistical analysis was
conducted using GraphPad Prism version 5.0 for Windows
(GraphPad Software; San Diego, California, USA).
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